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economic evaluations based on models, published in 2006 were
obtained from a PubMed search using terms “probabilistic sen-
sitivity” or “probabilistic uncertainty”. Methodological items
were extracted from each article and independently evaluated
against the criteria by each researcher. Disagreements between
evaluations were resolved through voting by the entire research
team. RESULTS: All 43 economic evaluations identiﬁed by the
search criteria were reviewed. 86% varied probability and
utility inputs but only a minority (25%) did so for cost and
resource use inputs. 79% of the studies reported parameter
ranges used in the PSA but only half provided rationale for the
ranges selected. The majority of analyses (65%) used a single
data source to inform distributions, rather than attempt to inte-
grate ﬁndings from multiple studies. Parameter correlation was
only addressed in one instance and only two studies incorpo-
rated structural uncertainty in their analyses. In half of the
studies, PSA was the only type of sensitivity analysis con-
ducted, with no one- or multi-way sensitivity analyses. Cost-
effectiveness acceptability curves derived from the PSAs were
presented in all cases. Less than 10% of studies discussed limi-
tations of their PSA. CONCLUSION: Although PSA has been
pushed as standard practice for economic evaluations, the
quality of these analyses was mixed. Greater consistency in
terms of inclusion of inputs varied and more transparency in
describing development of input probability distributions in the
conduct of PSAs should improve quality and cross-study com-
parability of results.
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OBJECTIVES: The Indigent Care Collaboration (ICC) gathers
data on hospital and clinic visits for medically indigent patients
in the Austin, Texas, area. However, obtaining cost data is
challenging within, and especially across, partner providers. A
validated cost model would be instrumental in developing pro-
grams and initiatives to improve care. The objectives of this
study were to estimate the annual costs of Austin, Texas, area
medically indigent patients and to describe the prevalence and
costs of chronic diseases and conditions using a diagnosis-based
risk adjustment model. METHODS: This study used the Diag-
nostic Cost Groups (DCG) prospective Medicaid All-
Encounters model, which uses diagnoses, age, and gender to
assign relative risk (RR) scores to patients. The RR scores were
multiplied by the per capita Texas Medicaid expenditure to
obtain estimated annual costs. Chronic diseases were described
in terms of prevalence and total estimated annual cost.
RESULTS: A total of 471,194 encounters were recorded for
163,729 patients meeting the study inclusion criteria between
March 1, 2004, and February 28, 2005. The mean estimated
patient yearly cost was $1,306.81, and the total estimated
yearly population cost was $228,909,529. The most common
chronic diseases and conditions included hypertension, diabe-
tes, depression, substance abuse, pregnancy, asthma, chronic
obstructive pulmonary disease (COPD), and congestive heart
failure (CHF). CONCLUSION: This study demonstrates how
the unknown costs associated with caring for medically indi-
gent patients in a community can be estimated at Medicaid
reimbursement rates using the DCG model on aggregated
patient encounter data.
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OBJECTIVES: The concept of efﬁcient frontier, given a series of
cost-effectiveness estimates for different levels of programs, plays
an important role in the incremental analysis. The purpose of the
study is to exploit a theoretical aspect of the incremental cost-
effectiveness ratios (ICERs) in the context of the efﬁcient frontier
curve, and then to identify the upper and lower limits that bound
the ICER, considering a potential application of the limits for the
pricing rule based on the ICER. METHODS: Let two points be
PA(Ea, Ca) and PB(Eb, Cb) for programs A and B, respectively,
on the E-C plane representing a set of effectiveness and cost.
Theoretical developments were undertaken to ﬁnd a solution for
the question on the boundaries, supposed there exists a concave
graph of the efﬁcient frontier curve, C = f(E), directing upward
from zero on the E-C plane. Model calculation was performed,
for an example, when the curve is a quadratic function estimated
as C = pE2 + qE + r (p, q, and r: constants). RESULTS: The inter-
val with the derivatives:(f ’(Ea), f ’(Eb)) on C = f(E), respectively,
at the points PA and PB was identiﬁed as a solution, called
‘operative interval,’ which describes reasonable lower/upper
boundaries of the ICER, considering the conﬁguration of the
graph. When the efﬁcient frontier curve is quadratic, the width of
the interval was estimated as 2p(DE). Namely, the width is vari-
able, not constant, depending on both p and DE. Furthermore,
the new benchmark identiﬁed four possible scenarios for making
a decision to accept the ICER compared with a threshold of
willingness-to-pay. CONCLUSION: The concept of the opera-
tive interval of an ICER has been introduced, and it suggested
potential usefulness for assessing the acceptability.
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OBJECTIVES: To explore the contribution made by disease
transmission modelling to cost effectiveness analyses.
METHODS: Traditional cost-effectiveness analysis quantiﬁes the
costs and effects accumulated by an average individual exposed
to a particular intervention, relative to one or more suitable
comparators. When reacting to an infectious disease, however,
many interventions alter the natural history of an infection or
individuals’ behaviour in ways that affect the onward transmis-
sion of the pathogen. This, in turn, may inﬂuence the number of
secondary infections generated by each infectious case. For a
cost-effectiveness analysis to account for the averted/additional
cases, a population level perspective including disease transmis-
sion modelling is required, but this comes at a cost. Transmission
models take time to construct and parameterise and are often
data hungry. Do the insights these models provide justify the
investment in time and expertise they require? RESULTS:
This exposition outlines the basic concepts underlying disease
transmission modelling, presents a simple model for a directly
transmitted disease (such as inﬂuenza) and demonstrates the
enormous impact population level effects can have on the
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